Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Esketamine ...

The FDA said this is the first time esketamine was approved for any use ... be monitored for "at least two hours" after receiving a dose and can't drive for the rest of the day.

and a safety follow-up through 2 weeks after the last dose of trial treatment (Fig. S1). After the screening phase, patients were randomly assigned, in a 1:1 ratio, to receive esketamine nasal ...

One low dose injection of esketamine administered right after childbirth reduces major depressive episodes in those with prenatal depression, according to a new study. When considering ketamine ...

Spravato (esketamine) is a nasal spray used for depression ... spray and you plan to use this the same day as your Spravato dose, take the steroid or decongestant nasal spray at least an hour ...

They receive esketamine at a certified doctor’s office or in a clinic, where a health care provider watches over them for at least two hours after the dose. (When the FDA first approved ...

The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an ...

for SPRAVATO ® (esketamine) CIII nasal spray, making this innovative treatment the first and only monotherapy for adults living with major depressive disorder (MDD) who have had an inadequate ...

"Many patients living with challenging-to-treat depression spend far too long cycling through multiple treatments that don't effectively resolve their symptoms, which can cause a significant ...